Trio Pharmaceuticals Appoints Patrick Doyle As Chief Executive Officer

Jul 18, 2025•3 days ago

Position

Chief Executive Officer

Company

Trio Pharmaceuticals

Patrick Doyle

San DiegoBiotechnology

Description

TRIO Pharmaceuticals has appointed Patrick Doyle as its new CEO, effective immediately. Mr. Doyle will focus on accelerating the development of TRIO’s innovative TRAILBody drugs.

Company Information

Company

Trio Pharmaceuticals

Location

11956 Bernardo Plaza Drive, Suite 160

San Diego, California, United States

About

TRIO Pharmaceuticals, Inc. is a cancer immunotherapeutics company pioneering bispecific antibodies for the treatment of cancer with unprecedented potency and selectivity. TRIO’s innovative antibody drugs directly stop tumor growth without affecting normal cells and selectively stop immunosuppression in the tumor without targeting the current immune checkpoint pathways. TRIO is developing a proprietary platform of dual-action tumor immunity-enhancing drugs aimed at treating cancers of high unmet medical needs by targeting specific antigens on the cancer cells and immunosuppressor cells. TRIO has an experienced team that has developed first-in-class FDA-approved drugs.

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months

Related People

Shivarupam hidden

hidden

Patrick hidden